Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (vol 378, pg 1931, 2011)

被引：0
|
作者：
Rini, B., I
Escudier, B.
Tomczak, P.
机构：
来源：
LANCET | 2012年 / 380卷 / 9856期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1818 / 1818
页数：1
相关论文
共 50 条
  • [41] Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK Perspective
    De Mello, Ramon Andrade
    Ayoub, Emili
    Castelo-Branco, Pedro
    De Almeida Zia, Victor Andre
    Savio, Andre
    Pozza, Daniel Humberto
    Tadokoro, Hakaru
    Teich, Nelson
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] Randomised phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 287 - 287
  • [43] Association of Single Nucleotide Polymorphisms (SNPs) in VEGF Pathway Genes With Progression-free Survival (PFS) and Blood Pressure (BP) in Metastatic Renal Cell Carcinoma (mRCC) in the Phase 3 Trial of Axitinib Versus Sorafenib (AXIS Trial)
    Escudier, B.
    Loomis, A. K.
    Kaprin, A.
    Motzer, R.
    Tomczak, P.
    Tarazi, J.
    Kim, S.
    Gao, F.
    Williams, J. A.
    Rini, B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S505 - S505
  • [44] Time to Deterioration (TTD) in Patient-reported Outcomes in Phase 3 AXis Trial of Axitinib Vs Sorafenib as Second-line Therapy for Metastatic Renal Cell Carcinoma (mRCC)
    Cella, D.
    Escudier, B.
    Rini, B.
    Chen, C.
    Bhattacharyya, H.
    Tarazi, J.
    Rosbrook, B.
    Kim, S.
    Motzer, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S224 - S224
  • [45] Sorafenib in advanced clear-cell renal-cell carcinoma (vol 356, pg 125, 2007)
    Escudier, Bernard
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (02): : 203 - 203
  • [46] Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial (vol 17, pg 995, 2016)
    Cella, D.
    Grunwald, V
    Nathan, P.
    LANCET ONCOLOGY, 2016, 17 (07): : E270 - E270
  • [47] Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial (vol 33, pg 172, 2015)
    Cainap, Calin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (22) : 2590 - 2590
  • [48] Safety and efficacy of second-line axitinib versus sorafenib in metastatic renal cell carcinoma by duration of prior therapy: Subanalyses from a phase III trial
    Escudier, B.
    Motzer, R. J.
    Lim, H. Y.
    Porfiri, E.
    Zalewski, P.
    Kannourakis, G.
    Tarazi, J.
    Rosbrook, B.
    Kim, S.
    Rini, B. I.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S673 - S674
  • [49] Re: Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
    Greco, Francesco
    Mirone, Vincenzo
    EUROPEAN UROLOGY, 2015, 68 (02) : 336 - 336
  • [50] Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma
    Escudier, Bernard
    Rini, Brian I.
    Motzer, Robert J.
    Tarazi, Jamal
    Kim, Sinil
    Huang, Xin
    Rosbrook, Brad
    English, Patricia A.
    Loomis, A. Katrina
    Williams, J. Andrew
    CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : 328 - U239
12345